Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Sees Significant Drop in Short Interest

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 1,927 shares, a decrease of 56.2% from the December 31st total of 4,399 shares. Based on an average trading volume of 11,509 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 11,509 shares, the days-to-cover ratio is currently 0.2 days.

Rocket Pharmaceuticals Stock Up 7.0%

RCKTW traded up $0.00 during mid-day trading on Thursday, reaching $0.02. The stock had a trading volume of 5,226 shares, compared to its average volume of 10,368. The firm’s fifty day simple moving average is $0.02 and its two-hundred day simple moving average is $0.03. Rocket Pharmaceuticals has a 52 week low of $0.01 and a 52 week high of $0.09.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.